EOM Pharmaceutical Holdings Inc. (IMUC)

[JJAAMMAANN]

ImmunoCellular Therapeutics Ltd (IMUC) Sees Large Growth in Short Interest

ImmunoCellular Therapeutics logoImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,709,519 shares, a growth of 1.8% from the October 31st total of 1,679,860 shares. Based on an average trading volume of 1,114,295 shares, the short-interest ratio is currently 1.5 days. Currently, 10.8% of the shares of the stock are sold short.

Separately, Maxim Group reissued a “hold” rating on shares of ImmunoCellular Therapeutics in a report on Thursday, August 24th.

Shares of ImmunoCellular Therapeutics (IMUC) traded down $0.01 on Wednesday, reaching $0.22. 7,178,955 shares of the company’s stock traded hands, compared to its average volume of 1,200,627. ImmunoCellular Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $4.27.

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.